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Introduction: Prevention and optimal management of hypertension in the general popu-
lation is paramount to the achievement of the WHF goal of reducing cardiovascular disease
mortality by 25% by the year 2025. Widespread access to good quality antihypertensive
medicines is a critical component for achieving the goal. Poor quality medicines including
those that are of substandard quality pose serious health concerns however, there remains a
knowledge gap about the quality of generic antihypertensive medicines especially in low-
middle income countries.
Objectives: To determine the quality of generic antihypertensive medicines available in the
retail market of a developing country.
Methods: We purchased samples of the two most commonly prescribed classes of anti-
hypertensive medicines from three states in three different geopolitical zones in Nigeria
following a semi-random sampling framework. Samples were purchased by a mystery
shopper from each of 24 pharmacy outlets from six local government areas (1 rural and 1
urban per state) across each of the three states. Samples were analyzed for content at the
London School of Hygiene and Tropical Medicine, bioanalytical facility. The stated active
pharmaceutical ingredient (SAPI) in each sample was measured using high-performance
liquid chromatography photodiode array detection with results expressed as percentage of
SAPI. Samples were classiﬁed as good quality (acceptable pharmaceutical quality, if
compliant with pharmacopeia tolerance limits of 90-110% SAPI), poor quality (sub-
standard, if contains either less or more than the acceptable dose, <90 ->110% SAPI) and
falsiﬁed (no SAPI).
Results: Amlodipine and Lisinopril were identiﬁed as the most commonly prescribed anti-
hypertensive drugs in Nigeria. In total, 440 samples from 24 pharmacies were collected and
tested. We found 69.4% of Amlodipine and 69.9% of Lisinopril samples were of acceptable
pharmaceutical quality. However, 30.6% of Amlodipine and 33.1% of Lisinopril samples
were of substandard quality. We did not detect any falsiﬁed samples of either Amlodipine
or Lisinopril.
Conclusion: About one-third of commonly prescribed anti-hypertensive drugs available in
Nigeria appear to be of substandard quality. Enhanced quality assurance processes in low-
middle income countries such as Nigeria are needed to support optimum management.
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Introduction: Despite the global epidemic of cardiovascular disease and the proven ben-
eﬁts of cardiac rehabilitation (CR), program availability and capacity have never been
characterized around the world.
Objectives: to establish CR availability, volumes and its’ drivers, density, and delivery
barriers.
Methods: Availability of any CR in every country of the world was identiﬁed via the
literature, and cardiac associations were consulted to conﬁrm. Champions from each
country with CR were enlisted to identify the number of programs and to administer them
an online survey, which assessed volumes and capacity. Factors associated with volumes
were assessed using generalized linear mixed models, and compared by World Health
Organization region. Density was computed using Global Burden of Disease study ischemic
heart disease (IHD) estimates.
Results: CR was available in 111/203 (54.7%) countries; data were collected in 93 (83.8%;
N¼1,082 surveys, 32.1% program response rate). Availability by region ranged from
85.2% of countries in Europe, to 17.0% in Africa (p<$001). There were 3,373 programs in
the world that could serve 1,675,270 patients/year, despite an estimated 20,611,675
incident IHD cases globally/year. Where available, the median CR volume was 157 patients/
program annually (interquartile range¼75-350); volume was signiﬁcantly greater where
patients were systematically referred (OR¼1.35, 95% CI 1.35-1.38) and programs offered
alternative models (OR¼1.05, 95% CI 1.04-1.06), and signiﬁcantly lower with private or
public funding (OR¼ 0.92, 95% CI 0.91-0.93 and OR¼0.83, 95% CI 0.82-0.84)
compared to hybrid sources, among others. Median capacity was 0 patients/country
globally. The CR density was one CR spot per 11 IHD cases in countries with CR, and 12
globally. Financial resources were the greatest barrier.
Conclusion: CR is available in only half of countries globally. Where offered, capacity is
grossly insufﬁcient to serve patients in need, such that most indicated patients will not
derive the beneﬁts associated with participation.
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Introduction: Hypertension is an important causes of premature death. In Kenya, 24% of
adults have High Blood Pressure (HBP) or are currently on medication. More than half of
Kenyans have never been screened, 92% of patients are not on treatment and only 3% on
treatment are controlled. With the shortage of human resources hypertension screening is
not carried out routinely at the health facilities. Community Health Volunteers (CHVs)
have been successfully used to increase uptake of health services in Kenya though they
remain underappreciated.
Objectives: The objective of this study is to document outcomes of utilizing CHVs in
hypertension screening and treatment.
Methods: Amref Health Aﬁrca through the Healthy Heart Africa project has been sup-
porting the Ministry of Health (MOH) to provide hypertension screening and treatment in
Nairobi, Kiambu and Kirinyaga counties since April 2015. A total of 279 CHV were trained
to provide hypertension screening at the health facility and community level and to link
those with HBP for diagnosis conﬁrmation and treatment by trained health workers at the
health facilities. Routinely collected data for the period April 2015 to December 2017 was
analysed retrospectively.
Results: Overall 253,734 participants were screened by CHVs during this period, 165,255
(65%) females and 160,314 (67%) aged below 40 years. Majority (60%) had their initial
screening done at a health facility. A total of 43,201 (17%) had HBP at initial screening with
males having a higher prevalence of HBP at 20% compared to females at 15%. A total of
8,333 (19%) with HBP were linked for diagnosed and treatment. Of those started on
treatment, 6447 (77%) were started on medication. Retention on treatment (deﬁned as
participants who had were not more than 180 days from their last clinic visit) was 49% as
at December 2017.
Conclusion: CHVs played a critical role in facilitating screening and diagnosis of hyper-
tension. Linkage to treatment and retention was low. Majority of clients reached were fe-
males. Further research is required on effective interventions to address these gaps and
inform future initiatives. The role of CHVs in hypertension management should be
recognized by the MOH and appropriate compensation provided.
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Introduction: Atrial ﬁbrillation (AF) is among the most common heart rhythm irregular-
ities, affecting 33 million people worldwide. During AF, the contractions of atria are
ineffective, resulting in blood stagnation and clot formation. This may travel to the brain
and cause ischemic stroke. In people aged over 80, approximately every third stroke is
caused by AF.
AF may cause symptoms, but many times AF is asymptomatic. Recognizing AF before
the outcome, stroke, has a major impact on health costs, not to mention the huge impact
on one’s life.
Objectives: We aimed to raise the awareness about the association between AF and
increased risk of stroke. We also aimed to teach citizens to palpate their own pulse.
Methods: The Finnish Heart Association and The Finnish Brain Association developed a
campaign called Know Your Pulse, carried out in 2012-2015.
Educational material and an animation with a twist of hilarity were created.
Volunteers from local and regional societies of the Associations educated people to
palpate wrists at marketplaces etc. countrywide.
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